RT Journal Article
SR Electronic
T1 Increased circulating IL-18 levels in severe mental disorders indicate systemic inflammasome activation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.28.21258013
DO 10.1101/2021.05.28.21258013
A1 Attila Szabo
A1 Kevin S. O’Connell
A1 Thor Ueland
A1 Mashhood A. Sheikh
A1 Ingrid Agartz
A1 Dimitrios Andreou
A1 Pål Aukrust
A1 Birgitte Boye
A1 Erlend Bøen
A1 Ole Kristian Drange
A1 Torbjørn Elvsåshagen
A1 John Abel Engh
A1 Sigrun Hope
A1 Margrethe Collier Høegh
A1 Inge Joa
A1 Erik Johnsen
A1 Rune Andreas Kroken
A1 Trine Vik Lagerberg
A1 Tove Lekva
A1 Ulrik Fredrik Malt
A1 Ingrid Melle
A1 Gunnar Morken
A1 Terje Nærland
A1 Vidar Martin Steen
A1 Kjetil Sørensen
A1 Kirsten Wedervang-Resell
A1 Melissa Auten Weibell
A1 Lars T. Westlye
A1 Nils Eiel Steen
A1 Ole Andreassen
A1 Srdjan Djurovic
YR 2021
UL http://medrxiv.org/content/early/2021/05/31/2021.05.28.21258013.abstract
AB Background Schizophrenia (SCZ) and bipolar disorder (BD) are severe mental illnesses (SMI) that are part of a psychosis continuum, and dysregulated innate immune responses have been suggested to be involved in their pathophysiology. However, disease-specific immune mechanisms in SMI are not known yet. Recently, dyslipidemia has been linked to systemic inflammasome activation, and elevated atherogenic lipid ratios have been shown to correlate with circulating levels of inflammatory biomarkers in SMI. It is, however, not yet known if increased systemic cholesterol load leads to inflammasome activation in these patients.Methods We tested the hypothesis that patients with SCZ and BD display higher circulating levels compared to healthy individuals of key members of the IL-18 system using a large patient cohort (n=1632; including 737 SCZ and 895 BD), and healthy controls (CTRL; n=1070). In addition, we assessed associations with coronary artery disease risk factors in SMI, focusing on relevant inflammasome-related, neuroendocrine, and lipid markers.Results We report higher baseline levels of circulating IL-18 system components (IL-18, IL-18BPA) as well as increased expression of inflammasome-related genes (NLRP3 and NLRC4) in the blood of patients relative to CTRL. We demonstrate a cholesterol dyslipidemia pattern in psychotic disorders, and report correlations between levels of blood cholesterol species and the expression of inflammasome system elements in SMI.Conclusions Based on these results, we suggest a link between systemic inflammasome activation/dysregulation and cholesterol load in SMI. Our findings further the understanding of possible underlying inflammatory and metabolic mechanisms and may expose important therapeutic targets in SMI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by The Research Council of Norway (223273, 262656, 248828), K.G. Jebsen Stiftelsen, South-East Norway Health Authority (2015-078, 2017-112), European Unions Horizon 2020 Research and Innovation Action Grant (847776 CoMorMent). T.E. was funded by the South-Eastern Norway Regional Health Authority 2015-078, the Ebbe Froland foundation, and a research grant from Mrs. Throne-Holst.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants gave written informed consent and the study was approved by the Norwegian Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate. All procedures and methods were carried out in accordance with relevant guidelines and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data referred to in the manuscript are included in the submitted material.